Apple introduced a redesigned Health app on 9 September 2026, adding a Health Age calculation and a Readiness score that blend wearable metrics with lab results from Quest Diagnostics’ 50‑biomarker panel priced at $119 for U.S. users.
Feature details and pricing
The new Insights tab in the Health app presents a Health Age metric that compares a user’s health data – including VO₂ max, sleep patterns and other fitness indicators – with their chronological age. A companion Readiness score offers actionable guidance on fitness and recovery. Apple Intelligence powers the calculations, and users can import lab results from Quest’s 50‑biomarker panel directly into the app. TechCrunch confirmed that the Quest panel costs $119 per test and is available to U.S. consumers at launch.
Apple‑Quest partnership
The partnership enables Apple’s software to incorporate clinical biomarker data that previously required separate lab visits. Quest Diagnostics, listed on the NYSE under ticker DGX, reported $5.938 billion in revenue for the six‑month period ending 30 June 2026, according to its latest Form 10‑Q filing. The $119 price point for the 50‑biomarker panel is the first consumer‑facing cost disclosed by the company for this service.
Sector impact
By merging consumer‑grade wearable data with clinical‑grade lab results, Apple is blurring the line between wellness apps and medical diagnostics. The move could encourage other device makers to seek similar lab‑integration partnerships, expanding the addressable market for diagnostic labs that traditionally serve physicians and hospitals. Analysts have noted that health‑tech firms that can offer end‑to‑end data pipelines may capture a larger share of the $500 billion U.S. digital health market, though the exact magnitude remains uncertain.
Financial backdrop
Apple’s scale provides context for the partnership’s potential reach. The company reported net income of $101.464 billion for the fiscal year ending 27 June 2026, as shown in its Form 10‑Q filing. Total assets stood at $383.266 billion, and shareholders’ equity was $107.520 billion at the same date. Apple’s shares outstanding were 14.6089 billion, per the same filing.
Quest Diagnostics, while much smaller, posted net income of $572 million for the six‑month period ending 30 June 2026. Its total assets were $16.939 billion and shareholders’ equity $7.516 billion. The revenue gap between the two firms underscores the asymmetry of the partnership: Apple brings a massive user base and data‑collection platform, while Quest supplies the clinical testing capability.
| Company | Revenue | Revenue period | Net income | Net income period | Source |
|---|---|---|---|---|---|
| Apple Inc. | USD 265.595 billion | Fiscal year 2018 (ended 29 Sept 2018) | USD 101.464 billion | Fiscal year 2026 (ended 27 June 2026) | SEC Form 10‑K/10‑Q filings |
| Quest Diagnostics Inc. | USD 5.938 billion | Six months ended 30 June 2026 | USD 572 million | Six months ended 30 June 2026 | SEC Form 10‑Q filing |
Outlook and unknowns
The rollout is limited to U.S. users at launch, and Apple has not disclosed pricing for the Health Age or Readiness features themselves. It also did not specify how many users are expected to adopt the Quest panel or whether the price will change for future tests. The partnership’s success will depend on consumer willingness to pay $119 for a lab test and on the perceived value of integrating those results into a wellness app.
Industry observers will watch whether other wearable makers, such as Fitbit or Garmin, pursue similar lab‑integration deals. If Apple’s approach gains traction, it could accelerate a broader shift toward data‑driven personal health management, prompting insurers and employers to consider incorporating such metrics into wellness programs.
For now, Apple’s Health app expansion adds a new revenue‑adjacent service to its ecosystem, while Quest gains a direct‑to‑consumer distribution channel for its diagnostic panel. The financial filings show both companies are financially robust, providing a solid foundation for the partnership to evolve.